Sugi Predict

Sugi Predict / Compounds / SCHEMBL7894841

SCHEMBL7894841

SCHEMBL7894841

CC(C)N1CCc2cc(F)ccc2C1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KCNH2 Q12809 4/20 0.50
▸ TMEM97 Q5BJF2 3/20 0.50
▸ SIGMAR1 Q99720 3/20 0.50
▸ DPP8 Q6V1X1 5/20 0.43
▸ DPP9 Q86TI2 5/20 0.43
▸ DPP7 Q9UHL4 5/20 0.43
▸ DPP4 P27487 4/20 0.43
▸ HRH3 Q9Y5N1 4/20 0.42
▸ NOTUM Q6P988 1/20 0.41
▸ MOGAT2 Q3SYC2 1/20 0.39
▸ HTR1A P08908 1/20 0.38
▸ DRD2 P14416 1/20 0.38
▸ HTR2A P28223 1/20 0.38
▸ SLC6A4 P31645 1/20 0.38
▸ HTR7 P34969 1/20 0.38
▸ DRD3 P35462 1/20 0.38
▸ HTR2B P41595 1/20 0.38
▸ MAOB P27338 1/20 0.38
▸ ASIC3 Q9UHC3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9963386 0.93 KCNH2 (0.50) KCNH2TMEM97SIGMAR1DPP8DPP9
SCHEMBL10057635 0.85 KCNH2 (0.59) KCNH2TMEM97SIGMAR1DPP8DPP9
SCHEMBL13499613 0.81 HRH3 (0.43) KCNH2DPP8DPP9DPP7HRH3
SCHEMBL26575966 0.80 HRH3 (0.42) HRH3MOGAT2HTR2ASLC6A4HTR2B
SCHEMBL24616867 0.79 HSD17B3 (0.42) HRH3MOGAT2ASIC3
SCHEMBL2741634 0.79 OGA (0.43) KCNH2HRH3MOGAT2ASIC3
SCHEMBL21361596 0.79 CARM1 (0.48) DPP8DPP9DPP7HRH3HTR2A
SCHEMBL21361477 0.79 HTR2A (0.44) KCNH2TMEM97SIGMAR1HRH3NOTUM
SCHEMBL12184930 0.79 HRH3 (0.42) KCNH2DPP7HRH3MOGAT2SLC6A4
SCHEMBL15142196 0.79 DRD1 (0.54) HRH3DRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 — — US disclosed
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 — — US disclosed
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 — — EP disclosed
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 — — US disclosed
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-12-22 — — US disclosed
WO-2022081927-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C4 THERAPEUTICS, INC. (US) 2022-04-21 — — WO disclosed
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2021-03-18 — — US disclosed
US-10676437-B2 Fluorinated 4-(substituted amino)phenyl carbamate derivatives SCIFLUOR LIFE SCIENCES, INC. (US) 2020-06-09 — — US disclosed
WO-2019178510-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2019-09-19 — — WO disclosed
US-20190177274-A1 FLUORINATED 4-(SUBSTITUTED AMINO)PHENYL CARBAMATE DERIVATIVES OCUTERRA THERAPEUTICS, INC. 2019-06-13 — — US disclosed
US-20160237071-A1 T-TYPE CALCIUM CHANNEL INHIBITOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2016-08-18 — — US disclosed
EP-3053917-A1 T-TYPE CALCIUM CHANNEL BLOCKER Nissan Chemical Industries, Ltd. (JP) 2016-08-10 — — EP disclosed
WO-2015050212-A1 T-TYPE CALCIUM CHANNEL BLOCKER 日産化学工業株式会社 2015-04-09 — — WO disclosed
WO-2010085246-A1 2,4-DIAMINO-1,3,5-TRIAZINE AND 4, 6-DIAMINO-PYRIMIDINE DERIVATIVES AND THEIR USE AS AGGRECANASE INHIBITORS PRAECIS PHARMACEUTICALS INC (US) 2010-07-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors SEC61B, SEC61A1, SEC61G KCNH2 4523/4885TMEM97 1269/4885SIGMAR1 2641/4885
US-20160237071-A1 T-TYPE CALCIUM CHANNEL INHIBITOR CACNA1I, CACNA1G, CACNA1H KCNH2 29/4885TMEM97 1782/4885SIGMAR1 578/4885
US-10676437-B2 Fluorinated 4-(substituted amino)phenyl carbamate derivatives KCNQ2, KCNQ1, KCNN3 KCNH2 14/4885TMEM97 1541/4885SIGMAR1 2482/4885
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY NFATC1, CTSS, MMP12 KCNH2 4811/4885TMEM97 3680/4885SIGMAR1 3709/4885
US-20190177274-A1 FLUORINATED 4-(SUBSTITUTED AMINO)PHENYL CARBAMATE DERIVATIVES KCNQ2, KCNQ1, KCNN3 KCNH2 14/4885TMEM97 1541/4885SIGMAR1 2482/4885
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G KCNH2 4564/4885TMEM97 963/4885SIGMAR1 2378/4885
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G KCNH2 4564/4885TMEM97 916/4885SIGMAR1 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.